Clinical trials
Myeloma clinical trials
Below are recruiting myeloma clinical trials, each written for real people, not researchers. We’re tracking 574 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03966443Recruiting
Fluciclovine PET/CT scan for people with multiple myeloma
This trial studies how a special PET/CT scan (using fluciclovine) may help doctors evaluate multiple myeloma. You might be eligible if you’re a candidate for stem cell transplant (ASCT).
OsloAges 18 years+ - NCT07280013RecruitingPhase 1
Cemsidomide with elranatamab for multiple myeloma
This trial tests a new drug combination (cemsidomide and elranatamab) for people with multiple myeloma that has come back after previous treatments. The goal is to see if the combination is safe and works better than current options.
Gilbert, ArizonaAges 18 years+ - NCT04025450RecruitingPhase 1/Phase 2
Tested stronger combo for high-risk myeloma patients
This early-phase study compares two drug combinations—chidamide plus VRD versus VRD alone—to see which works better for primary high-risk multiple myeloma. The goal is to improve response while closely monitoring side effects and heart/lung safety.
Suzhou, JiangsuAges 18–80 - NCT04211259RecruitingEarly Phase 1
Loratadine to reduce bone pain during stem cell collection
This early trial studies whether loratadine (an allergy medicine) can reduce bone pain caused by G-CSF, which is used to help your body collect stem cells. If you have multiple myeloma and are preparing for stem cell mobilization, this may make treatment-related bone pain more tolerable.
New Brunswick, New JerseyAges 18 years+ - NCT04234022Recruiting
Test a drug approach for multiple myeloma and leukemia
This trial studies a treatment aimed at a specific disease pathway in people with multiple myeloma or acute leukemia. It may help shrink or control cancer cells by targeting how they respond to low-oxygen conditions.
WolverhamptonAges 18 years+ - NCT04240054RecruitingPhase 2
Study drugs before transplant for myeloma with kidney problems
This Phase 2 trial tests whether a combination of anti-myeloma medicines given before stem cell transplant works well and is safe for people with multiple myeloma who also have kidney problems. It may help control the myeloma and prepare you for the transplant.
Milwaukee, WisconsinAges 18 years+ - NCT04268199RecruitingPhase 2
At-home chemotherapy teaching for people with myeloma
This study tests whether people with symptomatic myeloma can safely learn to give themselves chemotherapy at home. It aims to make treatment easier while tracking safety and whether treatment is done correctly.
Calgary, AlbertaAges 18 years+ - NCT04314752Recruiting
Study on multiple myeloma disparities in California patients
This study builds research tools to better understand and address differences in multiple myeloma outcomes for different groups. You may be able to help if you were diagnosed recently and live in California.
Sacramento, CaliforniaAges 21 years+ - NCT04349358Recruiting
PET/CT scan test to find bone lesions in new myeloma
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
BesançonAges 18–75 - NCT04414475RecruitingPhase 2
Selinexor plus low-dose steroid for hard-to-treat myeloma
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
Pátrai, AchaiaAges 18 years+ - NCT04483206RecruitingPhase 1
Personalized stem cell transplant for multiple myeloma
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Atlanta, GeorgiaAges 18 years+ - NCT04533217Recruiting
Vertebroplasty for multiple myeloma back pain
This trial tests whether adding a procedure called vertebroplasty to usual care can better reduce back pain from multiple myeloma. It’s for people who have a small number of spine fractures in a specific area and significant pain.
Middelfart, Region SyddanmarkAges 18 years+ - NCT04558931RecruitingPhase 2
NK cell therapy to help control multiple myeloma after initial treatment
This Phase 2 trial tests using your own immune cells (NK cells) alone or with isatuximab as “maintenance” treatment to help multiple myeloma stay under control after initial therapy. It may help lengthen the time until the disease grows again by boosting your immune response and targeting myeloma cells.
StockholmAges 18 years+ - NCT04603872RecruitingEarly Phase 1
CAR-T plus dasatinib for hard-to-treat B-cell cancers
This early study tests a cancer-fighting treatment that uses CAR-T cells together with dasatinib for people whose B-cell cancers have come back or did not respond. It aims to improve control of the cancer in cases that are often resistant to standard treatment.
Hangzhou, ZhejiangAges 18–70 - NCT04776395RecruitingPhase 2
Iberdomide to treat intermediate or high-risk smoldering myeloma
This Phase 2 study tests iberdomide alone or with low-dose dexamethasone in people with intermediate- or high-risk “smoldering” multiple myeloma. The goal is to see if the treatment can control or delay progression to active myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT04795882RecruitingPhase 1
Study of modular CAR T therapy for multiple myeloma
This early-phase study tests a personalized type of immune therapy called modular CAR T for people with relapsed or treatment-resistant multiple myeloma. It aims to see whether the therapy can reduce the myeloma, including in cases where standard treatments have not worked.
London, County (Optional)Ages 18 years+ - NCT05650632RecruitingPhase 1
IV infusion safety study of etentamig for multiple myeloma
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
Phoenix, ArizonaAges 18 years+ - NCT06106945RecruitingPhase 1/Phase 2
AZD0305 alone or with other drugs for multiple myeloma
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT05001087Recruiting
Patient and doctor registry for active multiple myeloma
This study creates a real-world registry (a group database) of people with active, symptomatic multiple myeloma. It helps researchers learn from patients and doctors over time and may support future research and treatment improvements.
Florence, FirenzeAges 18 years+ - NCT05055063RecruitingPhase 1
Belantamab for high-risk smoldering myeloma safety and early benefit
This Phase 1 trial tests belantamab mafodotin, a cancer medicine, in people with high-risk smoldering multiple myeloma to see how safe it is and whether it may shrink or control the disease. Because it’s an early-stage study, you would be closely monitored and treated with one main study drug.
Houston, TexasAges 18 years+ - NCT05091372RecruitingPhase 2
Maintenance treatment after transplant for newly diagnosed myeloma
This trial tests whether using belantamab mafodotin plus lenalidomide as long-term maintenance after an autologous stem cell transplant can keep multiple myeloma under control, guided by minimal residual disease (MRD). MRD is a very small amount of disease that may remain after transplant, and the study helps see if treating those patients better improves outcomes.
Houston, TexasAges 18 years+ - NCT05145400RecruitingPhase 2
Drug treatment for frail or older newly diagnosed multiple myeloma
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
Chapel Hill, North CarolinaAges 18 years+ - NCT05192122RecruitingPhase 1
Stop maintenance medicine in multiple myeloma with low remaining disease
This early-phase study looks at whether it’s safe to stop the usual “maintenance” medicine after a strong response in multiple myeloma. It aims to see if stopping treatment for people with very low remaining disease reduces drug exposure without allowing relapse too soon.
Chicago, IllinoisAges 18 years+ - NCT05203003Recruiting
Testing whether measurable cancer leftovers predict outcomes
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
ParisAges 18 years+
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloma?
- Yes. Clin2 currently lists 574 recruiting myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.